Also Known As
Islet Cell Cytoplasmic Autoantibodies
ICA
Insulin Autoantibodies
IAA
Glutamic Acid Decarboxylase Autoantibodies
GADA
Insulinoma-Associated-2 Autoantibodies
IA-2A
Formal Name
Diabetes-related Autoantibodies
This article was last reviewed on
This article waslast modified on
May 26, 2018.
At a Glance
Why Get Tested?

After a diagnosis of diabetes is made, to help distinguish autoimmune type 1 diabetes from type 2 diabetes

When To Get Tested?

When you are first diagnosed with diabetes to help determine whether your diabetes is autoimmune-related; when you are a diabetic who is treated with diet or drugs and have great difficulty maintaining normal or near-normal blood sugar (glucose) levels and are suspected of having type 1 instead of type 2 diabetes

Sample Required?

A blood sample drawn from a vein in your arm

Test Preparation Needed?

None

You may be able to find your test results on your laboratory's website or patient portal. However, you are currently at Lab Tests Online. You may have been directed here by your lab's website in order to provide you with background information about the test(s) you had performed. You will need to return to your lab's website or portal, or contact your healthcare practitioner in order to obtain your test results.

Lab Tests Online is an award-winning patient education website offering information on laboratory tests. The content on the site, which has been reviewed by laboratory scientists and other medical professionals, provides general explanations of what results might mean for each test listed on the site, such as what a high or low value might suggest to your healthcare practitioner about your health or medical condition.

The reference ranges for your tests can be found on your laboratory report. They are typically found to the right of your results.

If you do not have your lab report, consult your healthcare provider or the laboratory that performed the test(s) to obtain the reference range.

Laboratory test results are not meaningful by themselves. Their meaning comes from comparison to reference ranges. Reference ranges are the values expected for a healthy person. They are sometimes called "normal" values. By comparing your test results with reference values, you and your healthcare provider can see if any of your test results fall outside the range of expected values. Values that are outside expected ranges can provide clues to help identify possible conditions or diseases.

While accuracy of laboratory testing has significantly evolved over the past few decades, some lab-to-lab variability can occur due to differences in testing equipment, chemical reagents, and techniques. This is a reason why so few reference ranges are provided on this site. It is important to know that you must use the range supplied by the laboratory that performed your test to evaluate whether your results are "within normal limits."

For more information, please read the article Reference Ranges and What They Mean.

What is being tested?

Diabetes-related autoantibodies are proteins produced by the immune system that have been shown to be associated with type 1 diabetes. Testing can detect the presence of one or more of these autoantibodies in the blood.

Type 1 diabetes is a condition characterized by a lack of insulin due to autoimmune processes that destroy the insulin-producing beta cells in the pancreas. Diabetes-related autoantibodies reflect the destruction of beta cells, the loss of beta cell function, and inadequate production of insulin that are features of type 1 diabetes, but they are not thought to be the cause of type 1 diabetes. In contrast, type 2 diabetes primarily results from the body's resistance to the effects of insulin (insulin resistance) and does not involve autoimmune processes.

Type 1 diabetes was previously known as juvenile or insulin-dependent diabetes but has been re-characterized to reflect beta cell destruction. When autoimmune type 1 diabetes is present, one or more of the diabetes autoantibodies will be present in about 95% of those affected at the time of initial diagnosis. With type 2 diabetes, the autoantibodies are typically absent.

Four of the most common diabetes-related autoantibody tests include:

  • Islet Cell Cytoplasmic Autoantibodies (ICA)
  • Glutamic Acid Decarboxylase Autoantibodies (GADA)
  • Insulinoma-Associated-2 Autoantibodies (IA-2A)
  • Insulin Autoantibodies (IAA)

For more on these, see The Test tab.

About 5% of all cases of diabetes are type 1 (autoimmune) and the majority of these cases are diagnosed in people younger than 20. Symptoms of diabetes, such as frequent urination, thirst, weight loss, and poor wound healing, emerge when about 80-90% of a type 1 diabetic's beta cells have been destroyed and are no longer able to produce insulin. The body requires daily insulin so that glucose can enter cells and be used for energy production. Without sufficient insulin, cells starve and high blood sugar (hyperglycemia) results. Acute hyperglycemia can cause a diabetic medical crisis and chronic hyperglycemia can damage blood vessels and organs such as the kidneys.

How is the sample collected for testing?

A blood sample is obtained by inserting a needle into a vein in the arm.

Is any test preparation needed to ensure the quality of the sample?

No test preparation is needed.

Accordion Title
Common Questions
  • How is it used?

    Diabetes-related (islet) autoantibody testing is primarily used to help distinguish autoimmune type 1 diabetes from diabetes due to other causes. Type 1 diabetes is a condition characterized by a lack of insulin due to autoimmune processes that destroy the insulin-producing beta cells in the pancreas. Type 2 diabetes is primarily associated with insulin resistance.

    Determining which type of diabetes is present allows for early treatment with the most appropriate therapy to avoid complications from the disease. Type 1 diabetics must self-check their glucose levels and inject themselves with insulin several times a day to control the level of glucose in their blood. Type 2 diabetics may self-check their glucose one or more times a day. However, type 2 diabetics control their blood glucose in a variety of ways. Some can control their glucose levels with diet and exercise, others take oral medications, and some need daily insulin injections.

    The four most common autoantibody tests used to distinguish between type 1 diabetes and diabetes due to other causes are summarized in the table below.

    Test Abbr Description Comments
    Islet Cell Cytoplasmic Autoantibodies ICA Measures a group of islet cell autoantibodies targeted against a variety of islet cell proteins (Note: beta cells are one type of islet cell) One of the most common islet cell autoantibodies detected at onset of disease; detected in about 70-80% of newly diagnosed type 1 diabetics
    Glutamic Acid Decarboxylase Autoantibodies GADA Tests for autoantibodies directed against beta cell protein (antigen) but is not specific to beta cells Also one of the most commonly detected autoantibodies in newly diagnosed type 1 diabetics (about 70-80%)
    Insulinoma-Associated-2 Autoantibodies IA-2A Tests for autoantibodies directed against beta cell antigens but is non-specific Detected in about 60% of type 1 diabetics
    Insulin Autoantibodies IAA Autoantibody targeted to insulin; insulin is the only antigen thought to be highly specific for beta cells.

    Detected in about 50% of type 1 diabetic children; not commonly detected in adults

    IAA test does not distinguish between autoantibodies that target the endogenous insulin and antibodies produced against exogenous insulin.

    The autoantibodies seen in children are often different than those seen in adults. IAA is usually the first marker to appear in young children. As the disease evolves, this may disappear and ICA, GADA and IA-2A become more important. IA-2A is less commonly positive at the onset of type 1 diabetes than either GADA or ICA. Whereas about 50% of children with new-onset type 1 diabetes will be IAA positive, IAA positivity is not common in adults.

  • When is it ordered?

    A combination of these autoantibodies may be ordered when a person is newly diagnosed with diabetes and the health practitioner wants to distinguish between type 1 and type 2 diabetes. In addition, these tests may be used when the diagnosis is unclear in diabetics who have been diagnosed as type 2 but who have great difficulty in controlling their glucose levels with standard treatments.

  • What does the test result mean?

    If ICA, GADA, and/or IA-2A are present in a person with symptoms of diabetes, the diagnosis of type 1 diabetes is confirmed. Likewise, if IAA is present in a child with diabetes who is not insulin-treated, type 1 diabetes is the cause.

    If no diabetes-related autoantibodies are present, then it is unlikely that the diabetes is type 1. Some people who have type 1 diabetes will never develop detectable amounts of islet autoantibodies, but this is rare. The majority of people, 95% or more, with new-onset type 1 diabetes will have at least one islet autoantibody.

  • Is there anything else I should know?

    Because GADA and IA-2A assays are automated, these tests are generally more available than ICA testing, which is labor-intensive and requires considerable expertise in interpretation.

    Islet autoantibodies may also be seen in people with other autoimmune endocrine disorders such as Hashimoto thyroiditis or autoimmune Addison disease.

    Testing non-diabetic individuals for islet autoantibodies is recommended only as part of a research study. In research settings, these islet autoantibody tests may be used to help predict the development of type 1 diabetes in family members of those affected. In general, the more islet autoantibodies that a non-diabetic person has in their blood, the higher their risk for later developing type 1 diabetes. If a non-diabetic individual with one or more islet autoantibodies also has a low insulin response to the intravenous injection of glucose, their risk for type 1 diabetes can be high. More specifically, in first degree relatives of people with type 1 diabetes who have ICA and a low insulin response to intravenous injection of glucose, the risk of developing type 1 diabetes within 5 years is greater than 50%.

    Because there are currently no effective therapies to prevent type 1 diabetes, general population screening for islet autoantibodies or testing of first degree relatives of those with type 1 diabetes is not generally recommended, except for research purposes.

    People who are treated with insulin injections may begin to develop antibodies directed against the exogenous insulin. The IAA test does not distinguish between these types of antibodies and the autoantibodies directed against endogenous insulin. Therefore, this test is not valid for someone who has already been treated with injections of insulin. For example, someone who was thought to be a type 2 diabetic and who was treated with insulin injections cannot then have this test done to determine if he or she is a type 1 diabetic.

  • Can these tests be used to diagnose diabetes?

    No. Type 1 diabetes as well as other types are screened for, diagnosed, and monitored using tests for blood glucose and/or A1c. The autoantibody tests can be used after diabetes is already diagnosed to help differentiate between type 1 and type 2.

  • Do the autoantibodies ICA, GADA, and IA-2A destroy the beta cells?

    They are associated with beta cell destruction and reflect an ongoing autoimmune process, but they are not thought to cause the damage.

  • Does early detection of beta cell destruction allow its prevention?

    Not currently. What it does do is allow for diabetes to be addressed as soon as symptoms, such as frequent urination, weight loss, and high blood glucose (hyperglycemia), appear. This can help establish diabetic glucose control and can in turn help minimize the occurrence of complications, such as the kidney and eye damage that are seen with diabetes.

View Sources

Sources Used in Current Review

Topiwala, S. (Updated 2012 April 29). Anti-insulin antibody test. MedlinePlus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/003375.htm through http://www.nlm.nih.gov. Accessed March 2014.

(Updated 2014 February 5). Diabetes Overview. National Diabetes Information Clearinghouse (NDIC) [On-line information]. Available online at http://diabetes.niddk.nih.gov/dm/pubs/overview/ through http://diabetes.niddk.nih.gov. Accessed March 2014.

Khardori, R. (Updated 2013 December 6). Type 1 Diabetes Mellitus. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/117739-overview through http://emedicine.medscape.com. Accessed March 2014.

(© 1995–2014). Diabetes Mellitus Type 1 Evaluation. Mayo Clinic Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/60480 through http://www.mayomedicallaboratories.com. Accessed March 2014.

(February 2014). Overview of Diabetes in Children and Adolescents. National Diabetes Education Program (NDEP) [On-line information]. Available online at http://ndep.nih.gov/media/youth_factsheet.pdf through http://ndep.nih.gov. Accessed March 2014.

Lamb, W. (Updated 2013 September 16). Pediatric Type 1 Diabetes Mellitus. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/919999-overview through http://emedicine.medscape.com. Accessed March 2014.

Pagana, K. D. & Pagana, T. J. (© 2011). Mosby's Diagnostic and Laboratory Test Reference 10th Edition: Mosby, Inc., Saint Louis, MO. Pp 359-360.

McPherson, R. and Pincus, M. (© 2011). Henry's Clinical Diagnosis and Management by Laboratory Methods 22nd Edition: Elsevier Saunders, Philadelphia, PA. Pp 1016-1017.

(©2011) American Association of Clinical Endocrinologists. Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan. Available online at https://www.aace.com/files/dm-guidelines-ccp.pdf through https://www.aace.com. Accessed March 2014.

Sources Used in Previous Reviews

Maclaren, N. and Marker, J. (2002 December). Guidelines & Recommendations for Laboratory Analysis in the Diagnosis & Management of Diabetes Mellitus. Weill College of Medicine of Cornell University, NACB Laboratory Medicine Practice Guidelines [On-line information]. Available online at http://www.nacb.org/temporary/Maclaren2.htm through http://www.nacb.org.

Kimpimäki, T. et. al. (2000). Disease-Associated Autoantibodies as Surrogate Markers of Type 1 Diabetes in Young Children at Increased Genetic Risk. Journal of Clinical Endocrinology & Metabolism Vol 85 No. 3 1126-1132 [On-line information]. Available online at http://jcem.endojournals.org/cgi/content/full/85/3/1126 through http://jcem.endojournals.org.

Borg, H. et. al. (2001). High Levels of Antigen-Specific Islet Antibodies Predict Future ß-Cell Failure in Patients with Onset of Diabetes in Adult Age. The Journal of Clinical Endocrinology & Metabolism 86 (7): 3032. (2001) [On-line journal]. Available online at http://jcem.endojournals.org/cgi/reprint/86/7/3032 through http://jcem.endojournals.org.

Achenbach, P. et. al. (2004). Stratification of Type 1 Diabetes Risk on the Basis of Islet Autoantibody Characteristics. Diabetes 53:384-392 [On-line journal]. Available online at http://diabetes.diabetesjournals.org/cgi/content/full/53/2/384 through http://diabetes.diabetesjournals.org.

(© 2005). Glutamic Acid Decarboxylase (GAD) Antibody. ARUP's Guide to Clinical Laboratory Testing [On-line information]. Available online at http://www.arup-lab.com/guides/clt/tests/clt_a287.jsp#1149613 through http://www.arup-lab.com.

(© 2005). Islet Cell Antibody, IgG. ARUP's Guide to Clinical Laboratory Testing [On-line information]. Available online at http://www.arup-lab.com/guides/clt/tests/clt_a25b.jsp#1153005 through http://www.arup-lab.com.

(© 2005). IA-2 Antibody. ARUP's Guide to Clinical Laboratory Testing [On-line information]. Available online at http://www.arup-lab.com/guides/clt/tests/clt_alpb.jsp#2441172 through http://www.arup-lab.com.

Dupré, J. & Mahon, J. (2000 August). Diabetes-Related Autoantibodies and the Selection of Subjects for Trials of Therapies to Preserve Pancreaticß-Cell Function in Recent-Onset Type 1 Diabetes. Diabetes Care, (23): 8 [On-line information]. Available online through http://care.diabetesjournals.org.

Rewers, M. (2005 October, Updated). Type I Diabetes: Molecular, Cellular, and Clinical Immunology, Chapter 9 Epidemiology of Type I Diabetes. Barbara Davis Center for Childhood Diabetes, UCDHSC [On-line information]. Available online at http://www.uchsc.edu/misc/diabetes/oxch9.html through http://www.uchsc.edu.

Eisenbarth, G. (2003 November). Chapter 11 Prediction of Type I Diabetes: The Natural History of the Prediabetic Period. Type I Diabetes: Molecular, Cellular, and Clinical Immunology, Barbara Davis Center for Childhood Diabetes, UCDHSC [On-line information]. Available online at http://www.uchsc.edu/misc/diabetes/oxch11.html through http://www.uchsc.edu.

Winter, WE. Diabetes disease management: differentiating type 1 and type 2 diabetes. Clinical Laboratory News. 2005; 31(7):14-16.

Winter, W.E. Autoimmune Disorders that Influence Carbohydrate Metabolism (Chapter 24). In: Clinical and Laboratory Evaluation of Human Autoimmune Diseases. Nakamura R.M., Keren, D.F., Bylund D.J. (eds): ASCP Press, Chicago, 2002, Pp:345-372.

Winter, W.E. Autoimmune Endocrinopathies. In: Pediatric Endocrinology, Fourth Edition, F. Lifshitz (ed): Marcel Dekker, Inc., New York, New York, 2003, Pp 683-720.

Winter, W.E. and Signorino, M. R. Immunologic Disorders in Infants and Children (5th edition). In: Autoimmune Endocrinopathies. E.R. Stiehm (ed), W.B. Saunders Company, Philadelphia, Pennsylvania, 2004, Pp 1179-1221.

William Winter, M.D. Professor of Pathology and Pediatrics, University of Florida School of Medicine, Gainesville, FL.

Hussain, A. and Vincent, M. (Updated 2009 July 2). Diabetes Mellitus, Type 1. eMedicine On-line information]. Available online at http://emedicine.medscape.com/article/117739-overview through http://emedicine.medscape.com. Accessed January 2010.

Titus, K. (2009 August). Diabetes markers—closer than you think? CAP Today [On-line information]. Available online through http://www.cap.org. Accessed January 2010.

(2008 May). Overview of Diabetes in Children and Adolescents. National Diabetes Education Information [On-line information]. Available online at http://ndep.nih.gov/media/diabetes/youth/youth_FS.htm through http://ndep.nih.gov. Accessed January 2010.

S4 Pagana, K. D. & Pagana, T. J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 355-356.

Clarke, W. and Dufour, D. R., Editors (© 2006). Contemporary Practice in Clinical Chemistry: AACC Press, Washington, DC. Pp 292-293.

Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 620-621, 630-631.

Kronenberg, H. et. al. (© 2008). Williams Textbook of Endocrinology, 11th Edition: Saunders Elsevier, Philadelphia, PA. Pp 1399.

Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL eds (2005). Harrison's Principles of Internal Medicine, 16th Edition, McGraw Hill, Pg 2156.

Matti Ankelo, et al. Time-Resolved Immunofluorometric Dual-Label Assay for Simultaneous Detection of Autoantibodies to GAD65 and IA-2 in Children with Type 1 Diabetes. Clinical Chemistry. 2007;53:472-479.

Henry's Clinical Diagnosis and Management by Laboratory Methods. 21st ed. McPherson R, Pincus M, eds. Philadelphia, PA: Saunders Elsevier: 2007, 956.

Ask a Laboratory Scientist

 

Your questions will be answered by a laboratory scientist as part of a voluntary service provided by one of our partners, the American Society for Clinical Laboratory Science (ASCLS). Click on the Contact a Scientist button below to be re-directed to the ASCLS site to complete a request form. If your question relates to this web site and not to a specific lab test, please submit it via our Contact Us page instead. Thank you.

Contact a Scientist